Cargando…

Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer

BACKGROUND: Adjuvant trastuzumab improves survival for women with human epidermal growth factor receptor 2‐positive breast cancer, but increases risk for heart failure (HF) and cardiomyopathy (CM). However, clinical trials may underestimate HF/CM risk because they enroll younger subjects with fewer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ezaz, Ghideon, Long, Jessica B., Gross, Cary P., Chen, Jersey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959671/ https://www.ncbi.nlm.nih.gov/pubmed/24584736 http://dx.doi.org/10.1161/JAHA.113.000472

Ejemplares similares

High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy
por: Katsurada, Kenichi, et al.
Publicado: (2014)

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group
por: Mackey, J.R., et al.
Publicado: (2008)

Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
por: Xu, Qiaoping, et al.
Publicado: (2021)

Hepatotoxicity induced by trastuzumab used for breast cancer adjuvant therapy: a case report
por: Ishizuna, Kazuo, et al.
Publicado: (2014)

A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients
por: Matos, Erika, et al.
Publicado: (2016)

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK
por: Earl, H.M., et al.
Publicado: (2021)

Early Cardiotoxicity after Adjuvant Concomitant Treatment with Radiotherapy and Trastuzumab in Patients with Breast Cancer
por: Marinko, Tanja, et al.
Publicado: (2018)

Extra-pancreatic complications, especially hemodialysis predict mortality and length of stay, in ICU patients admitted with acute pancreatitis
por: Kothari, Darshan, et al.
Publicado: (2018)

Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study
por: Blondeaux, Eva, et al.
Publicado: (2020)

Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
por: Bowles, Erin J. Aiello, et al.
Publicado: (2012)

Dilated cardiomyopathy following trastuzumab chemotherapy
por: Karmakar, Saurabh, et al.
Publicado: (2012)

Cost-Effectiveness Analysis of Trastuzumab in the Adjuvant Treatment for Early Breast Cancer
por: Aboutorabi, Ali, et al.
Publicado: (2015)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
por: Sardesai, Sagar, et al.
Publicado: (2020)

Cardiac Monitoring and Heart Failure in Advanced Breast Cancer Patients Treated With Trastuzumab in Ontario, Canada
por: Rushton, Moira, et al.
Publicado: (2022)

Cardiovascular Risk After Adjuvant Trastuzumab in Early Breast Cancer: An Italian Population‐Based Cohort Study
por: Franchi, Matteo, et al.
Publicado: (2020)

Predicting Heart Failure in Arrhythmogenic Right Ventricular Cardiomyopathy
por: Hylind, Robyn J., et al.
Publicado: (2020)

Predicting Heart Failure in Arrhythmogenic Right Ventricular Cardiomyopathy
por: Wang, Weijia, et al.
Publicado: (2022)

Immunoadsorption Therapy for Patients with Dilated Cardiomyopathy and Heart Failure
por: Ikeda, Uichi, et al.
Publicado: (2008)

Efficacy and safety of short course adjuvant trastuzumab combination chemotherapy in breast cancer
por: Hingmire, Sachin S., et al.
Publicado: (2017)

Influenza vaccination in breast cancer patients during subcutaneous trastuzumab in adjuvant setting
por: Joona, Therse Björkin, et al.
Publicado: (2020)

Adjuvant trastuzumab: progress, controversies, and the steps ahead
por: Joy, A.A., et al.
Publicado: (2006)

Effectiveness of adjuvant trastuzumab in daily clinical practice
por: Matos, Erika, et al.
Publicado: (2014)

miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer
por: Nielsen, Boye Schnack, et al.
Publicado: (2014)

Effectiveness of trastuzumab as adjuvant therapy in patients with early stage breast cancer: A systematic review and meta-analysis
por: Davari, Majid, et al.
Publicado: (2017)

Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study
por: Li, Junjie, et al.
Publicado: (2018)

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
por: Genuino, Anne Julienne, et al.
Publicado: (2019)

MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab
por: Cataldo, Alessandra, et al.
Publicado: (2018)

Cabergoline as an adjuvant to standard heart failure treatment in peripartum cardiomyopathy: A case report and review of the literature
por: Caruso, Giuseppe, et al.
Publicado: (2020)

A Case of Trastuzumab-Associated Cardiomyopathy Presenting as an Acute Coronary Syndrome: Acute Trastuzumab Cardiotoxicity
por: Hidalgo, Sylvana, et al.
Publicado: (2013)

Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice
por: Gallagher, Christopher M., et al.
Publicado: (2016)

Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
por: Lluch-Gómez, J., et al.
Publicado: (2023)

Machine Learning for Predicting Heart Failure Progression in Hypertrophic Cardiomyopathy
por: Fahmy, Ahmed S., et al.
Publicado: (2021)

Radiation Recall Reaction Induced by Adjuvant Trastuzumab (Herceptin)
por: Chung, Caroline, et al.
Publicado: (2009)

Ischemic Cardiomyopathy and Heart Failure After Acute Myocardial Infarction
por: Del Buono, Marco Giuseppe, et al.
Publicado: (2022)

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab
por: Jacquinot, Quentin, et al.
Publicado: (2022)

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
por: Antonarelli, G., et al.
Publicado: (2023)

A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment
por: Du, F., et al.
Publicado: (2016)

Heart Failure in Patients with Arrhythmogenic Cardiomyopathy
por: Chen, Shi, et al.
Publicado: (2021)

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
por: Pondé, Noam, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5qrkr3vv2usq6kmp72fqeg2n3q